2018 Volume 34 Issue 4 Pages 337-341
I review disease concept and recent developments in understanding and treating 4 repeat tauopathies including corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). PSP and CBD are now considered pathologic diagnoses, with several different and varied clinical phenotypes, that overlap and share features with Parkinson disease, frontotemporal dementia, and spinocerebellar ataxia. New diagnostic criteria have been proposed for CBD and PSP. Because therapeutic interventions that target abnormally–phosphorylated tau have started, further refinement of the diagnostic criteria is needed via biomarker researches with prospective study designs.
